Department of Medicine, Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Diabetol Metab Syndr. 2010 Mar 18;2:16. doi: 10.1186/1758-5996-2-16.
To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release formulation of metformin (metformin XR) in hospital based outpatients with type 2 diabetes mellitus currently treated with standard metformin.
Patients on immediate release standard metformin either alone or combined with other oral agents were switched to extended release metformin XR 500 mg tablets and titrated to a maximum dose of 2000 mg/day Measurements to include glucose and lipid control, blood pressure, body weight, waist circumference, C-reactive protein, adverse events and patient satisfaction were recorded at baseline, three and six months.
Complete data were obtained for 35 of the 61 patients enrolled to the study. At three and six months no changes were reported for any of the cardiovascular risk factors except for lipids where there was a modest rise in plasma triglycerides. These effects were achieved with a reduced dose of metformin XR compared to pre-study dosing with standard metformin (1500 mg +/- 402 vs 1861 +/- 711 p = 0.004). A total of 77% of patients were free of gastrointestinal side effects and 83% of patients stated a preference for metformin XR at the end of the study. Ghost tablets were reported in the faeces by the majority of the patients (54.1%).
Patients switched to extended release metformin XR derived the same clinical and metabolic benefits as for standard metformin but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication.
前瞻性评估二甲双胍缓释制剂（二甲双胍 XR）在目前接受标准二甲双胍治疗的 2 型糖尿病住院门诊患者中的疗效、耐受性和患者满意度。
将正在服用普通速释标准二甲双胍或与其他口服药物联合使用的患者转换为二甲双胍 XR 500mg 缓释片，并滴定至最大剂量 2000mg/天。在基线、3 个月和 6 个月时记录血糖和血脂控制、血压、体重、腰围、C 反应蛋白、不良反应和患者满意度等测量结果。
共有 61 名入组患者中的 35 名完成了完整的数据收集。在 3 个月和 6 个月时，除了血浆三酰甘油略有升高外，所有心血管危险因素均无变化。与标准二甲双胍（1500mg+/-402 vs 1861mg+/-711，p=0.004）相比，使用二甲双胍 XR 可减少剂量，从而达到这些效果。77%的患者无胃肠道副作用，83%的患者在研究结束时表示更喜欢二甲双胍 XR。大多数患者（54.1%）的粪便中出现了“幽灵片”。
转换为二甲双胍 XR 缓释制剂的患者获得了与标准二甲双胍相同的临床和代谢益处，但剂量减少、胃肠道副作用减少、药物治疗的舒适度和满意度提高。
